MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…
MaaT PharmaJune 13, 2025
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…
MaaT PharmaApril 28, 2025
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…
MaaT PharmaMarch 31, 2025
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…
MaaT PharmaMarch 18, 2025
MaaT Pharma Announces Positive Topline Results from the Pivotal Phase 3 ARES Study Evaluating MaaT013…
MaaT PharmaJanuary 8, 2025
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the…
MaaT PharmaJanuary 7, 2025
MaaT Pharma Presented Positive Updated Data on MaaT013 in the Early Access Program at ASH…
MaaT PharmaDecember 10, 2024
MaaT Pharma Announces First U.S. Patient Treated at City of Hope Under Single Patient Expanded…
MaaT PharmaDecember 5, 2024
MaaT Pharma Completes Recruitment of its ARES Phase 3 Trial for MaaT013 to Treat Acute…
MaaT PharmaOctober 15, 2024
